Is there a role for Radium-223 in patients that have a non-prostate malignancy who otherwise would be a reasonable candidate?  

At present the only approved indication for Radium-223 is in castrate resistant, symptomatic bone mets from prostate cancer. We do have open study evaluating efficacy in hormone positive breast cancer with metastases to bone.